This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2016 by Amie E. Jones, M.D., Mayo Clinic
Information provided by (Responsible Party):
Amie E. Jones, M.D., Mayo Clinic Identifier:
First received: June 7, 2013
Last updated: September 15, 2016
Last verified: September 2016
This study is designed to investigate whether the treatment of non-anemic iron deficiency with intervenous iron sucrose will result in decreased symptom reporting and improved cardiovascular indices in adolescents (age 12-21) with Postural Orthostatic Tachycardia Syndrome (POTS).

Condition Intervention Phase
Postural Orthostatic Tachycardia Syndrome Drug: Iron infusion Drug: Normal saline infusion Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Double Blinded Clinical Trial of Intravenous Iron Sucrose in Adolescents With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)

Resource links provided by NLM:

Further study details as provided by Amie E. Jones, M.D., Mayo Clinic:

Primary Outcome Measures:
  • Cardiovascular indices-Intraval change in heart rate during 10-minute head up tilt table test [ Time Frame: 7 (+/- 2) days following intervention ]
    This study will assess whether a single infusion of iron sucrose will improve cardiovascular indices, specifically a reduction in the intraval of measured heart rate change, during a ten minute head up tilt, in adolescent subjects with POTS and non-anemic iron deficiency

Estimated Enrollment: 30
Study Start Date: October 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Iron infusion
Iron Sucrose (Venofer (R))
Drug: Iron infusion
5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
Other Names:
  • Iron sucrose
  • Venofer (TM)
Placebo Comparator: Normal saline infusion
Equal volume to intervention of normal saline
Drug: Normal saline infusion
Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
Other Names:
  • Normal saline
  • NaCl 0.9%


Ages Eligible for Study:   12 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • aged 12-21 years
  • chronic (>3 months)symptoms of orthostatic intolerance (including but not limited to lightheadedness, syncope, headache, fatigue, weakness, sweating, nausea and palpitations)
  • symptomatic orthostatic heart rate increase of greater than or equal to 40 beats per minute during a 10 minute 70 degree head up tilt study
  • presence of non-anemic iron deficiency, defined as serum ferritin level less than or equal to 20 ug/L with normal hemoglobin

Exclusion criteria

  • orthostatic hypotension within 3 minutes of 70 degree head up tilt
  • pregnant or lactating females
  • presence of other organ failure or systemic illness that can affect autonomic function
  • concurrent medication therapy with anticholinergic, alpha-adrenergic antagonists, beta-adrenergic antagonists unless medication is held for five half-lives prior to study
  • laboratory evidence of anemia or iron overload
  • personal history of hematochromatosis or first degree relative with hematochromatosis
  • known sensitivity to Venofer (TM) or other intravenous iron preparations
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01978535

United States, Minnesota
Mayo Clinic in Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Tonette Gehrking    507-284-4462      
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Amie Jones, MD Mayo Clinic
  More Information

Responsible Party: Amie E. Jones, M.D., PI, Mayo Clinic Identifier: NCT01978535     History of Changes
Other Study ID Numbers: 12-009963
Study First Received: June 7, 2013
Last Updated: September 15, 2016

Keywords provided by Amie E. Jones, M.D., Mayo Clinic:

Additional relevant MeSH terms:
Anemia, Iron-Deficiency
Postural Orthostatic Tachycardia Syndrome
Pathologic Processes
Anemia, Hypochromic
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Orthostatic Intolerance
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases
Ferric oxide, saccharated
Ferric Compounds
Trace Elements
Growth Substances
Physiological Effects of Drugs
Hematinics processed this record on August 23, 2017